• KimDo YoungDYDepartment of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea., Sang Hoon Ahn, Seung Up Kim, Sae Byeol Choi, Kwang-Hun Lee, Mi Sook Park, Jun Yong Park, LeeDo YunDY, Kwang-Hyub Han, and Kyung Sik Kim.
• Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea.
• Oncology. 2011 Jan 1; 81 (3-4): 184-91.

ObjectivesWe investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection.MethodsBetween January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls.ResultsTumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355).ConclusionAdjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.Copyright © 2011 S. Karger AG, Basel.

33 keywords...

hide…